Insmed Incorporated (NASDAQ:INSM) Q4 2023 Earnings Conference Call February 22, 2024 8:30 AM ET

Company Participants

Bryan Dunn – Head-Investor Relations

Will Lewis – Chairman and Chief Executive Officer

Sara Bonstein – Chief Financial Officer

Conference Call Participants

Nick Lenard – J.P. Morgan

Jennifer Kim – Cantor Fitzgerald

Tiago Fauth – Wells Fargo

Andrea Tan – Goldman Sachs

Joseph Schwartz – Leerink Partners

Ritu Baral – TD Cowen

Vamil Divan – Guggenheim Securities

Jeff Hung – Morgan Stanley

Liisa Bayko – Evercore

Stephen Willey – Stifel

Leiyang Wang – Barclays

Andy Chen – Wolfe Research

Jason Zemansky – Bank of America

Operator

Good day, and welcome to the Insmed Incorporated Fourth Quarter and Full Year 2023 Financial Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers’ remarks, there will be a question-and-answer session. [Operator Instructions] And finally, I would like to advise all participants this call is being recorded. Thank you.

I’d now like to welcome Bryan Dunn, Head of Investor Relations to begin the conference. Bryan, over to you.

Bryan Dunn

Thank you, Gavin. Good day, everyone, and welcome to today’s conference call to discuss Insmed’s fourth quarter 2023 financial results and provide a business update. I’m joined today by Will Lewis, Chair and Chief Executive Officer; and Sara Bonstein, Chief Financial Officer, who will each provide prepared remarks before we open it up for your questions.

Before we start, please note that today’s call will include forward-looking statements based on our current expectations. These statements represent our judgment as of today and inherently involve risks and uncertainties that may cause actual results to differ materially from the results discussed. Please refer to our filings with the Securities and Exchange Commission for more information concerning the risk factors that could affect the company. The information on today’s call is for the benefit of the investment community, it is not intended for promotional purposes and it is not sufficient for prescribing decisions.

I will now turn the call over to Will Lewis for prepared remarks.

Will Lewis

Thank you, Bryan. Good morning, everyone. I’m pleased to be speaking with you today at the start of what I believe will be a uniquely transformational year for Insmed. In just the next few months, we expect meaningful data readouts and other relevant updates from across our late-stage portfolio, the results of which could fundamentally change the trajectory for our company and the patients we serve.